{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:59Z","timestamp":1792587779466,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013924","name":"Vienna Business Agency","doi-asserted-by":"publisher","award":["4123094"],"award-info":[{"award-number":["4123094"]}],"id":[{"id":"10.13039\/501100013924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.biopha.2025.118041","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T08:33:36Z","timestamp":1744619616000},"page":"118041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Glioblastoma targeting by water-soluble hypericin derivate HHL-PVP and photodynamic tumour killing"],"prefix":"10.1016","volume":"186","author":[{"given":"Djenana","family":"Vejzovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4950-4594","authenticated-orcid":false,"given":"Andreas","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-2438","authenticated-orcid":false,"given":"Karoline","family":"Fechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Karner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ackerbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Radovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-3833","authenticated-orcid":false,"given":"Muammer","family":"\u00dc\u00e7al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ropele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kariem Mahdy","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-0792","authenticated-orcid":false,"given":"Mario","family":"Mischkulnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Liegl-Atzwanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9830","key":"10.1016\/j.biopha.2025.118041_bib1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(11)61346-9","article-title":"Primary brain tumours in adults","volume":"379","author":"Ricard","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.biopha.2025.118041_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10172","key":"10.1016\/j.biopha.2025.118041_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118041_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149244","article-title":"Safety and efficacy of 5-aminolevulinic acid for high grade glioma in usual clinical practice: a prospective cohort study","volume":"11","author":"Teixidor","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2025.118041_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3171\/2022.11.JNS22693","article-title":"Optimizing maximum resection of glioblastoma: Raman spectroscopy versus 5-aminolevulinic acid","volume":"139","author":"Herta","year":"2023","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.biopha.2025.118041_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118041_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","article-title":"Diffuse glioma heterogeneity and its therapeutic implications","volume":"11","author":"Nicholson","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118041_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fpls.2016.00560","article-title":"Hypericin in the light and in the dark: two sides of the same coin","volume":"7","author":"Jend\u017eelovsk\u00e1","year":"2016","journal-title":"Front Plant Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118041_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0304-3835(99)00381-X","article-title":"Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumour model","volume":"150","author":"Chen","year":"2000","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1078\/0944-7113-00057","article-title":"Photodynamic therapy of murine fibrosarcoma with topical and systemic administration of hypericin","volume":"8","author":"Cavarga","year":"2001","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.biopha.2025.118041_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pdpdt.2011.04.003","article-title":"Low dose hypericin-PDT induces complete tumour regression in BALB\/c mice bearing CT26 colon carcinoma","volume":"8","author":"Sanovic","year":"2011","journal-title":"Photodiagnosis. Photodyn. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118041_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-007-9514-0","article-title":"Hypericin-mediated photodynamic therapy of pituitary tumours: preclinical study in a GH4C1 rat tumour model","volume":"87","author":"Cole","year":"2008","journal-title":"J. Neurooncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib15","first-page":"1401","article-title":"Hypericin-mediated photodynamic therapy induces lipid peroxidation and necrosis in nasopharyngeal cancer","volume":"23","author":"Du","year":"2003","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118041_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.1594","article-title":"Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumours: implication for whole bladder wall photodynamic therapy","volume":"97","author":"Kamuhabwa","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2025.118041_bib17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamadermatol.2022.2749","article-title":"Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): the FLASH phase 3 randomized clinical trial","volume":"158","author":"Kim","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118041_bib18","first-page":"543","article-title":"Solubility of hypericin in methanol and methanol-pyridine","volume":"57","author":"Wirz","year":"2002","journal-title":"Pharmazie"},{"issue":"2","key":"10.1016\/j.biopha.2025.118041_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11547-014-0433-9","article-title":"Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis","volume":"120","author":"Qi","year":"2015","journal-title":"Radio. Med"},{"issue":"6","key":"10.1016\/j.biopha.2025.118041_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/1061186X.2013.789034","article-title":"Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis","volume":"21","author":"Kong","year":"2013","journal-title":"J. Drug Target"},{"issue":"47","key":"10.1016\/j.biopha.2025.118041_bib21","doi-asserted-by":"crossref","first-page":"29486","DOI":"10.1039\/D1RA05658A","article-title":"A novel multimodal nanoplatform for targeting tumour necrosis","volume":"11","author":"Han","year":"2021","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.biopha.2025.118041_bib22","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1021\/js970004a","article-title":"Binding, uptake, and transport of hypericin by Caco-2 cell monolayers","volume":"86","author":"Sattler","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118041_bib23","unstructured":"Kubin, A., \"hypericin-pvp complex with high hypericin content\", in European Patent Office, E.P. Office, Editor."},{"issue":"4","key":"10.1016\/j.biopha.2025.118041_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.31083\/ph.2008.7292","article-title":"How to make hypericin water-soluble","volume":"63","author":"Kubin","year":"2008","journal-title":"Pharmazie"},{"issue":"25","key":"10.1016\/j.biopha.2025.118041_bib25","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1038\/onc.2015.390","article-title":"TGF-\u03b2 signaling links E-cadherin loss to suppression of nucleotide excision repair","volume":"35","author":"Qiang","year":"2016","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2025.118041_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184439","article-title":"E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness","volume":"12","author":"Rosso","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2025.118041_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1464-410X.2005.05316.x","article-title":"In vivo accumulation of different hypericin ion pairs in the urothelium of the rat bladder","volume":"95","author":"Huygens","year":"2005","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib28","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.juro.2007.12.038","article-title":"Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin","volume":"179","author":"Huygens","year":"2008","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.urolonc.2010.07.006","article-title":"Altered expression of cell adhesion molecules leads to differential uptake of hypericin in urothelial cancer","volume":"30","author":"Olivo","year":"2012","journal-title":"Urol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118041_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2025.118041_bib31","article-title":"Detection of a water-soluble hypericin formulation in glioblastoma tissue with fluorescence lifetime and intensity using a dual-tap CMOS camera system","volume":"14","author":"Mischkulnig","year":"2024","journal-title":"Diagn. (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2025.118041_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1562\/0031-8655(2001)074<0221:TSAPCO>2.0.CO;2","article-title":"Tumour-specific and photodependent cytotoxicity of hypericin in the human LNCaP prostate tumour model","volume":"74","author":"Xie","year":"2001","journal-title":"Photochem. Photobio."},{"key":"10.1016\/j.biopha.2025.118041_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1477-7819-4-87","article-title":"Photodynamic therapy and tumour imaging of hypericin-treated squamous cell carcinoma","volume":"4","author":"Head","year":"2006","journal-title":"World J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1562\/2006-02-22-RA-806","article-title":"Hypericin-induced photocytotoxicity is connected with G2\/M arrest in HT-29 and S-phase arrest in U937 cells","volume":"82","author":"Sackov\u00e1","year":"2006","journal-title":"Photochem. Photobio."},{"issue":"4","key":"10.1016\/j.biopha.2025.118041_bib35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1039\/c0pp00359j","article-title":"Lower sensitivity of FHC fetal colon epithelial cells to photodynamic therapy compared to HT-29 colon adenocarcinoma cells despite higher intracellular accumulation of hypericin","volume":"10","author":"Mike\u0161","year":"2011","journal-title":"Photochem. Photobio. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118041_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103762","article-title":"St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death","volume":"9","author":"Kleemann","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2025.118041_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejso.2011.12.021","article-title":"Hypericin for visualization of high grade gliomas: first clinical experience","volume":"38","author":"Ritz","year":"2012","journal-title":"Eur. J. Surg. Oncol."},{"issue":"6b","key":"10.1016\/j.biopha.2025.118041_bib38","first-page":"4651","article-title":"Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin","volume":"18","author":"Alecu","year":"1998","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.biopha.2025.118041_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1751-1097.2007.00260.x","article-title":"Photodynamic therapy of nonmelanoma skin cancer with topical Hypericum perforatum extract--a pilot study","volume":"84","author":"Kacerovsk\u00e1","year":"2008","journal-title":"Photochem. Photobio."},{"issue":"6","key":"10.1016\/j.biopha.2025.118041_bib40","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2010.02.039","article-title":"A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis","volume":"63","author":"Rook","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.biopha.2025.118041_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/837152","article-title":"Botanical agents for the treatment of nonmelanoma skin cancer","volume":"2013","author":"Millsop","year":"2013","journal-title":"Dermatol. Res. Pract."},{"issue":"8","key":"10.1016\/j.biopha.2025.118041_bib42","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118041_bib43","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/ol.2016.4113","article-title":"Epithelial-mesenchymal transition in glioblastoma progression","volume":"11","author":"Iwadate","year":"2016","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2025.118041_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/glia.23520","article-title":"Astrocytes, the rising stars of the glioblastoma microenvironment","volume":"67","author":"Brandao","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118041_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110086","article-title":"Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumour immune microenvironment in glioblastoma","volume":"126","author":"Zhang","year":"2020","journal-title":"Biomed. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:59:23Z","timestamp":1781823563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225002355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"alternative-id":["S0753332225002355"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118041","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glioblastoma targeting by water-soluble hypericin derivate HHL-PVP and photodynamic tumour killing","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118041"}}